Sorry, the correct answer is C. Long-acting injectable PrEP (either CAB-LA, dosed every 2 months intramuscularly; or lenacapavir, dosed every 6 months subcutaneously) was developed specifically for patients whose adherence, privacy, or lifestyle needs make daily oral dosing difficult. It would be inappropriate to focus only on daily oral PrEP when the patient has suggested that this option does not fit her lifestyle. Presenting injectable options as an alternative supports informed, patient-centered choice and helps preserve continuity of protection. Efficacy of on-demand PrEP was established in studies conducted in men who have sex with men and transgender women; due to a lack of data, it is not recommended for people who may have HIV exposures due to vaginal sex.